PEPTIDE CANCER VACCINE MARKET ANALYSIS

Peptide Cancer Vaccine Market, by Pipeline Phase (Research, Preclinical, Phase-I, Phase-I/II, Phase-II, and Phase III), by Application (Colorectal Cancer, Lung Cancer, Pancreatic Cancer, Gastric Cancer, Prostate Cancer, and Breast Cancer), and by Region - Global Insights, Industry Trends, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Nov 2024
Code : CMI1634
Formats :
Excel and PDF
Industry : Biotechnology

Regional Analysis

Global Peptide Cancer Vaccine Market - Regional Insights

North America accounted for the largest share in the global peptide cancer vaccine market, followed by Europe in 2016. This is attributed to presence of a high number of top pharmaceutical and biotech companies in this region such as Pfizer, Inc., Novartis, Merck, GlaxoSmithKline, and Roche. Moreover, increasing prevalence of cancer is also expected to foster the market growth. According to the National Cancer Institute, 2016, an estimated 16.8 million new cases of cancer were diagnosed in the U.S., with an approximate 595,690 deaths from the disease. The number of people with cancer is expected to rise to 19 million by 2024.

Moreover, several pharmaceutical and biotechnological companies are focusing on expanding in Asia Pacific and conducting R&D activities to offer better access to patients for clinical trials and to offer low cost operational efficiencies. Increasing government investment in research and development also fosters growth of the global peptide cancer vaccine market in Asia Pacific.

Geographies Covered